We are a team of dedicated professionals who are committed in providing excellent cardiac care based on current best practices and the needs of our patients.
Our vision is to be a leading cardiology service in Asia based on current best practices and guidelines, at a competitive price.
We are committed to being the best in what we do and putting the patient’s interest first.
We are a team of professionals who strive to cooperate and work closely together to achieve the best outcomes for our patients.
We act with integrity and adhere to the highest ethical standards.
We aim to achieve the highest standards of cardiac care and will continually strive to improve our service standards to match or exceed our patient’s expectations.
At Novena Heart Centre, we believe that research is an integral part of clinical practise. It is necessary to help develop new capabilities and to remain at the forefront of medical science. It also challenges us to think out of the box and question our current practices in order to innovate and come up with better solutions for the patients.
Currently, we are involved in three research projects.
- Long term (3 years) opthalmic safety and cardiac efficacy and safety of ivabradine administered orally at therapeutic doses on top of anti-anginal background therapy, to patients with chronic stable angina pectoris. An international double-blind placebo controlled study. Dr. Kenneth Ng is the country co-ordinator for this study which involves the National Eye Centre, National Heart Centre and Changi General Hospital.
- Intima-Media thickness guidance of Primary prevention in Relatives of individuals with Early onset atherosclerosis: The IMPRESS Study- a multi-centre randomised controlled trial. Novena Heart Center is proud to be one of the two centers in Singapore which is involved in a ground breaking study to determine if guiding management with the carotid intima media thickness would change outcomes for patients. Dr. Raymond Lee and Dr. Kenneth Ng are involved in this study.
- The Coronary Artery Disease Risk Assessment (CADRA) Study. This is a collaborative study between the National University of Singapore and Novena Heart Centre to develop a novel test to screen asymptomatic individuals as young as from birth to determine their lifetime risk for developing cardiovascular events. Dr. Jimmy Lim is our co-ordinator for this study.
- Prevalence of the CYP2C19 polymorphism in Singapore.CYP2C19 codes for genes that could affect the effectiveness of a commonly prescribed drug called clopidogrel (Plavix).